Real-world durability of effectiveness through 24 months of anti-interleukin (IL)-17A biologics and other approved biologics in treating patients with moderate-to-severe psoriasis in the Psoriasis Study of Health Outcomes (PSoHO)
In this medfyle
Part of making individualised recommendations for patients involves understanding how different classes impact certain outcomes and goals. A new analysis explores durability of effectiveness over 2 years in a real-world cohort of psoriasis patients on biologics.
About this Medfyle
©2024 Infomedica-Medfyle. All rights reserved.
Source: Real-world durability of effectiveness through 24 months of anti-interleukin (IL)-17A biologics and other approved biologics in treating patients with moderate-to-severe psoriasis in the Psoriasis Study of Health Outcomes (PSoHO). Tijoe M, et al. Presented at EADV 2024; P3354; Abstract #6239.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
